UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of ~~the~~

the Securities Exchange Act of 1934

Date of Report: ~~October~~March 191, ~~2012~~2013

(Date of earliest event reported)

SCOLR Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-31982

91-1689591

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

13400 NE 20^th Street, Suite 44

Bellevue, Washington 98005

(Address of principal executive offices and zip code)

(425) 368-1050

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 12.~~01.~~04 ~~Entry~~Triggering ~~into~~Events athat ~~Material~~Accelerate ~~Agreement~~or Increase A Direct Financial Obligation or an Off-Balance Sheet Arrangement.

~~On October 21, 2012,~~ SCOLR Pharma, Inc., a Delaware corporation (the “Company” ~~or “SCOLR”~~), ~~and~~ceased ~~RedHill~~its ~~Biopharma~~business ~~Ltd.,~~operations anon ~~Israeli~~March 1, ~~corporation~~2013. ~~(“RedHill”),~~The ~~entered~~cessation ~~into~~of aoperations ~~term~~may ~~sheet,~~constitute ~~effective~~an asevent of ~~October 19th~~default ~~2012,~~under ~~which~~the ~~sets~~Company’s ~~forth~~outstanding ~~certain~~8% ~~terms~~Senior ~~and~~Secured ~~conditions~~Convertible ofDebentures adue ~~contemplated~~June, ~~license~~2013. ~~agreement~~The ~~between~~Company has $2,545,200 principal amount outstanding under the ~~parties~~debentures.

The ~~term~~Debentures ~~sheet~~are ~~contemplates~~secured ~~the~~by ~~negotiation~~all ofthe ~~a definitive license agreement under which RedHill would obtain exclusive worldwide rights to develop, market and sell formulations of two drugs based on SCOLR~~Company’s ~~proprietary~~assets ~~controlled~~pursuant ~~delivery~~to ~~technology~~a ~~(CDT®).~~Security Agreement ~~The~~dated ~~first drug is ibuprofen~~June 16, an2011 ~~analgesic~~among ~~for~~ the ~~treatment~~Company ~~of pain~~ and ~~inflammation.~~CSC ~~The~~Trust ~~second~~Company ~~drug~~of isDelaware ~~pseudoephedrine,~~as acollateral ~~decongestant~~agent ~~for~~ (the ~~treatment~~“Security ~~of cough and cold~~Agreement”). ~~The~~Upon ~~term~~certain ~~sheet~~events ~~sets forth the basic terms~~ of ~~the~~default, ~~contemplated definitive license agreement. The terms include an agreement by RedHill to use diligent efforts to obtain regulatory approval for~~ the ~~two~~holders ~~drugs and to bring them to market. The term sheet also provides for payments to SCOLR to be made at specified rates based on the aggregate net sales~~ of the ~~licensed~~Debentures ~~products.~~may ~~The term sheet contemplates that SCOLR would~~ be entitled to ~~royalties~~accelerate ~~based on net sales of~~ the ~~products actually~~ ~~received by RedHill ranging between 20% and 50% for ibuprofen, and between 8% and 15% for pseudoephedrine, depending in each case upon the territory in which such net sales are derived, RedHill~~Company’s ~~role~~obligations inunder the ~~distribution~~Debentures ~~of the products~~ and ~~certain~~ ~~other~~exercise ~~factors.~~available ~~The~~remedies ~~term~~under ~~sheet~~the ~~does~~Security ~~not contemplate any advance or milestone payments payable to SCOLR~~Agreement.

~~The~~Following ~~license~~an ~~transaction~~event ~~contemplated by the term sheet is subject to the satisfactory completion~~ of ~~due diligence by RedHill~~default, ~~the~~interest ~~execution~~on ~~of a definitive licensing agreement and certain other conditions. The term sheet includes binding provisions (i) prohibiting SCOLR from engaging in negotiations with any other party related to~~ the ~~products~~Debentures ~~contemplated~~accrues toat ~~be licensed to RedHill for~~ a ~~period~~rate of ~~ninety (90)~~18% ~~days~~per ~~and (ii) requiring payments to be made under certain circumstances in which either party fails to execute the definitive licensing agreement following satisfactory completion of due diligence~~annum.

~~This~~Item 5.02 ~~current~~Departure ~~report on Form 8-K contains forward-looking statements (statements which are not historical facts) within the meaning~~ of ~~the Private~~ ~~Securities~~Directors Litigation Reform Act of 1995, including statements regarding expected revenue impact of the Amendment referred to herein. These forward-looking statements involve risks and uncertainties, including activities, events or ~~developments~~Certain ~~that we~~Officers; ~~expect,~~Election ~~believe or anticipate will or may occur in the future. A number~~ of ~~factors~~Directors; ~~could~~Appointment ~~cause actual results to differ from those indicated in the forward-looking statements, including the completion~~ of ~~definitive~~Certain ~~documentation~~Officers; ~~and~~Compensatory ~~due diligence,~~Arrangements ~~receipt~~ of ~~necessary~~Certain ~~approvals and consents, and general economic conditions~~Officers. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

In connection with the cessation of its operations described in Item 2.04 above, the Company terminated its remaining employees, including its Chief Executive Officer, Stephen J. Turner, effective March 1, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCOLR PHARMA, INC.
Dated: October 23, 2012	By:	/s/ Stephen J. Turner
Dated: March 4, 2013	By:	/s/ Carl J. Johnson
		President and Chief Executive Officer
		Chairman of the Board of Directors

Filing Compare · SCOLR Pharma, Inc.